Claims for Patent: 7,825,246

Summary for Patent: 7,825,246

Title:	Bi-aryl meta-pyrimidine inhibitors of kinases
Abstract:	The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases. ##STR00001##
Inventor(s):	Noronha; Glenn (Oceanside, CA), Mak; Chi Ching (San Diego, CA), Cao; Jianguo (San Diego, CA), Renick; Joel (San Diego, CA), McPherson; Andrew (San Diego, CA), Zeng; Binqi (San Diego, CA), Pathak; Ved P. (San Diego, CA), Lohse; Daniel L. (San Diego, CA), Hood; John D. (San Diego, CA), Soll; Richard M. (San Diego, CA)
Assignee:	TargeGen, Inc. (San Diego, CA)
Application Number:	11/796,717
Patent Claims:	1. A compound having the structure (B): ##STR00580## wherein: X is selected from a group consisting of a bond, O, C.dbd.O, SO.sub.2, and CH.sub.2; Y is selected from a group consisting of a bond and NR.sup.9; or X and Y taken together is a bond; R.sup.9 is selected from a group consisting of H, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 cycloalkyl, C.sub.1-C.sub.6 branched alkyl, C.sub.1-C.sub.6 aminoalkyl, and C.sub.1-C.sub.6 hydroxyalkyl; each of R.sup.1 is independently selected from a group consisting of H, C.sub.1-C.sub.6 alkyl, cycloalkyl, and heterocycle; each of n, or p is independently an integer having the value between 0 and 6; Q.sub.1 is a 4-7 membered heterocycle connected through carbon or nitrogen, with one or more heteroatoms in the heterocyle, and each carbon or nitrogen in the heterocycle is optionally substituted independently with C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkenyl, C.sub.1-C.sub.6 alkynyl, C.sub.1-C.sub.6 hydroxyalkyl or aminoalkyl, C.sub.1-C.sub.6 branched alkyl, C.sub.1-C.sub.6 cycloalkyl, aryl connected through carbon or a heteroatom, a halogen, CF.sub.3, --OCF.sub.3, NO.sub.2, CN, OH, CONR.sup.3R.sup.4, and COR.sup.3; each of R.sup.6, R.sup.7, R.sup.8 is independently selected from a group consisting of H, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkenyl, C.sub.1-C.sub.6 alkynyl, C.sub.1-C.sub.6 hydroxyalkyl or aminoalkyl, C.sub.1-C.sub.6 branched alkyl, C.sub.1-C.sub.6 cycloalkyl, aryl, C.sub.1-C.sub.6 alkoxy, a halogen, CF.sub.3, --OCF.sub.3, CHR.sup.3R.sup.4, SR.sup.3, SOR.sup.3, SO.sub.2R.sup.3, SO.sub.2NR.sup.3R.sup.4, SO.sub.3R.sup.3, POR.sup.3, PO.sub.2R.sup.3, PO.sub.2NR.sup.3R.sup.4, PO.sub.2CR.sup.3R.sup.4, PO.sub.3R.sup.3, NR.sup.3R.sup.4, NO.sub.2, CN, OH, CONR.sup.3R.sup.4, COR.sup.3, COOR.sup.3, NR.sup.3COR.sup.4, NR.sup.3CONR.sup.3R.sup.4, OCONR.sup.3R.sup.4, CSNR.sup.3R.sup.4, CSR.sup.3, NR.sup.3CSNR.sup.3R.sup.4, SCONR.sup.3R.sup.4, and SCSNR.sup.3R.sup.4; or any of R.sup.6 and R.sup.7 taken together, or R.sup.7 and R.sup.8 taken together, or R.sup.6 and R.sup.8 taken together form a moiety independently selected from a group consisting of --HN--CH.dbd.CH--, --HN--N.dbd.CH--, --HN--N.dbd.N--, --O(CH.sub.2).sub.nO--, --S(CH.sub.2).sub.nS--, --N.dbd.CH--S--, --CH.dbd.N--O--, --CH.dbd.N--S--, --N.dbd.CH--O--, --C.dbd.N--O--, --CH.dbd.CH--CH.dbd.CH--, --N.dbd.CH--CH.dbd.CH--, --CH.dbd.N--CH.dbd.CH--, --O--CH.dbd.CH--, and --S--CH.dbd.CH--; each of R.sup.3 and R.sup.4 is independently selected from a group consisting of H, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 hydroxyalkyl or aminoalkyl, and C.sub.1-C.sub.6 branched alkyl, with the further provisos that: (a) at least one of R.sup.6, R.sup.7 and R.sup.8 is not hydrogen; (b) R.sup.6 and R.sup.7, or R.sup.6 and R.sup.8, or R.sup.7 and R.sup.8 are substituted with non-hydrogen atoms, or if only one of R.sup.6, R.sup.7 and R.sup.8 is substituted, then the substitution contains at least three non-hydrogen atoms; (c) any one of R.sup.6, R.sup.7 or R.sup.8 optionally comprises a heteroatom selected from a group consisting of O, N and S; and (d) the moiety Q.sub.1 excludes hetero-aromatic cyclic rings, or a pharmaceutically acceptable salt, or an individual diastereomer of the compound (B). 2. The compound of claim 1, having the structure (C): ##STR00581## 3. The compound of claim 1 having the structure (D): ##STR00582## wherein the moiety attached to a connection point shown in structure (D) is selected from a group consisting of: ##STR00583## 4. The compound of claim 1, having the structure (E): ##STR00584## 5. The compound of claim 1, having the structure (F): ##STR00585## wherein the moiety attached to a connection point shown in structure (F) is selected from a group consisting of: ##STR00586## 6. The compound of claim 1, having the structure (G): ##STR00587## 7. The compound of claim 1, having the structure (H): ##STR00588## wherein the moiety attached to a connection point shown in structure (H) is selected from a group consisting of: ##STR00589## 8. The compound of claim 1, having the structure (I): ##STR00590## wherein the moiety attached to a connection point shown in structure (H) is selected from a group consisting of: ##STR00591## 9. The compound of claim 1, having the structure (J): ##STR00592## wherein the moiety attached to a connection point shown in structure (J) is ##STR00593##